@article{ad8310e8ba8f45578bf4399315ee3371,
title = "Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenstr{\"o}m's macroglobulinemia",
abstract = "Marginal Zone Lymphoma (MZL) and Waldenstr{\"o}m's Macroglobulinemia (WM) are indolent lymphomas that both arise from post germinal center lymphocytes. Both can secrete a monoclonal protein but high levels are mostly only seen in WM. The MYD88 L256P somatic mutation that is present in an estimated 95% of patients with WM has helped greatly in differentiating the two lymphomas. Several large clinical studies with new drugs have been performed that have provided new treatment options for both MZL and WM patients. In this short review we will discuss the recent literature published and provide some recommendations.",
keywords = "marginal zone lymphoma, treatment, Waldenstrom macroglobulinemia",
author = "Karima Amaador and Catherine Thieblemont and Judith Trotman and Minnema, {Monique C}",
note = "Funding Information: Karima Amaador; none. Catherine Thieblemont: honoraria from Roche, Amgen, Janssen, Celgene, Gilead Science/Kyte Beigene; consulting/advisory role for Roche, Gilead Sciences, Janssen, Celgene, Novartis, Beigene, BMS/Celgene research funding and travel, accommodations, expenses from Roche, Novartis. Judith Trotman; Research funding from Roche, Takeda, Beigene, Cellectar, Janssen, BM. Monique Minnema; Consulting for Janssen Cilag, GSK, CDR life, Pfizer. Speakers Bureau Janssen Cilag, BMS, WebMD, Research funding Beigene Publisher Copyright: {\textcopyright} 2023 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.",
year = "2024",
month = nov,
doi = "10.1002/hon.3210",
language = "English",
volume = "42",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "John Wiley & Sons Inc.",
number = "6",
}